DOI QR코드

DOI QR Code

개에서 피모벤단-펜톡시필린 분말 제형 합제의 경구투여시 약물약동학 및 약물약력학에 대한 연구

Pharmacokinetics and Pharmacodynamics Following Oral Administration of Pimobendan-Pentoxifylline Powder Formulation Mixture in Dogs

  • 노웅빈 (건국대학교 수의과대학) ;
  • 송두원 (건국대학교 수의과대학) ;
  • 강여림 (건국대학교 수의과대학) ;
  • 박유진 (건국대학교 수의과대학) ;
  • 유초롱 (건국대학교 수의과대학) ;
  • 이종호 (건국대학교 수의과대학) ;
  • 김기훈 (호서대학교 바이오의과학연구소) ;
  • 정상희 (호서대학교 바이오의과학연구소) ;
  • 강민희 (건국대학교 수의과대학)
  • Ro, Woong-bin (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Song, Doo-won (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Kang, Yeo-lim (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Park, You-jin (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Yoo, Cho-rong (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Lee, Jong-ho (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Kim, Ki-hun (Biomedical Science Research Institute, Hoseo University) ;
  • Jeong, Sang-hee (Biomedical Science Research Institute, Hoseo University) ;
  • Kang, Min-hee (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
  • 투고 : 2019.01.17
  • 심사 : 2019.01.24
  • 발행 : 2019.02.28

초록

Pimobendan has inotropic and vasodilating effects on cardiovascular system, and pentoxifylline is known to decrease blood viscosity and improve blood flow to the heart. This study investigated the pharmacokinetics and pharmacodynamics following oral administration of pimobendan-pentoxifylline powder mixture in dogs. Eight healthy dogs were included and were divided into control (n = 4) and experimental (n = 4) groups. Vehicle powder and pimobendan-pentoxifylline powder mixture (pimobendane 0.25 mg/kg, pentoxifylline 15 mg/kg) were administrated orally to control and experimental groups, respectively. Plasma samples and measurement of echocardiographic indices were obtained for 24 hours following administration. Pimobendan and pentoxifylline concentrations were investigated using liquid chromatography-mass spectrometer (LC-MS) assay. The elimination half-life ($T_{1/2}$) were $2.65{\pm}1.42hours$ for pimobendan and $0.29{\pm}0.23hours$ for pentoxifylline. The time to reach maximum concentration ($T_{max}$) were $1.08{\pm}0.72hours$ for pimobendan and $0.29{\pm}0.14hours$ for pentoxifylline. The maximum blood concentration ($C_{max}$) were $2.83{\pm}1.50ng/mL$ for pimobendan and $1184.33{\pm}932.37ng/mL$ for pentoxifylline. Among echocardiographic indices, fractional shortening (FS), left ventricular internal diameter at end systole (LVIDs), and pre-ejection period (PEP) showed significant changes at 1-4 hours after the administration of pimobendan-pentoxifylline powder mixture. No adverse effects were observed during the investigation. This study demonstrates that pimobendan-pentoxifylline powder mixture can be used to control cardiovascular diseases in dogs.

키워드

참고문헌

  1. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 1142-1150. https://doi.org/10.1111/j.1939-1676.2009.0392.x
  2. Bell E, Devi J, Chiu S, Zahra P, Whittem T. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs. J Vet Pharmacol Ther 2016; 39: 54-61. https://doi.org/10.1111/jvp.12235
  3. Boehringer Ingelheim. Clinical pharmacology. In: Vetmedin Detail Sheet. Ingelheim am Rhein, Germany: Boehringer Ingelheim. 2007: 2.
  4. Bowton DL, Stump DA, Prough DS, Toole JF, Lefkowitz DS, Coker L. Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease. Stroke 1989; 20: 1662-1666. https://doi.org/10.1161/01.STR.20.12.1662
  5. Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care 2012; 22: 398-408. https://doi.org/10.1111/j.1476-4431.2012.00768.x
  6. Cornell CC, Kittleson MD, Torre PD, Haggstrom J, Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric scaling of M?mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18: 311-321. https://doi.org/10.1111/j.1939-1676.2004.tb02551.x
  7. Marsella R, Nicklin CF, Munson JW, Roberts SM. Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am J Vet Res 2000; 61: 631-637. https://doi.org/10.2460/ajvr.2000.61.631
  8. O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008; 22: 897-904. https://doi.org/10.1111/j.1939-1676.2008.0116.x
  9. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 1996; 91: 296-307. https://doi.org/10.1007/BF00789302
  10. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97. https://doi.org/10.2165/00003495-198734010-00003
  11. Yata M, McLachlan A, Foster D, Page S, Beijerink N. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs. J Vet Pharmacol Ther 2016; 39: 45-53. https://doi.org/10.1111/jvp.12243
  12. Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 2004; 9: 103.